At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 683 enrolled
Drug / intervention
Progesterone +1 moredrug
Likely dose
Progesterone 25 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Efficacy and Tolerability of Subcutaneous Progesterone Versus Vaginal Progesterone Gel for Luteal Phase Support in Patients Undergoing In-Vitro Fertilization (IVF)
In Brief
A Phase 3 clinical trial evaluating Progesterone for In Vitro Fertilization. Completed, enrolled 683 participants across 14 sites in 5 countries.
Detailed Summary
Prospective, open, randomised, parallel, multicentre, two arm trial comparing a new form of luteal support (S.C.) to an approved comparator (vaginal gel).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsIn Vitro Fertilization
CountriesGermany, Hungary, Italy, Switzerland, United Kingdom
Collaborators--
Timeline
Phase 3CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartJan 2009
First PostedJan 2009
Primary CompletionNov 2010
Study CompletionMay 2011
TodayJul 2026
First PostedJan 23, 2009
Enrollment StartJan 1, 2009
Primary CompletionNov 1, 2010
Study CompletionMay 1, 2011
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 17.4 years ago
Interventions
Progesteronedrug
25 mg, s.c., once à day
Progesteronedrug
90 mg, vaginally, once à day